ARS Pharmaceuticals (SPRY) Current Deferred Revenue (2020 - 2026)

ARS Pharmaceuticals has disclosed Current Deferred Revenue across 7 years of filings, most recently posting $757000.0 for Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $757000.0, up 40.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $757000.0 (up 40.19% YoY), and the FY2025 annual result was $609000.0, up 9.34% from the prior year.
• Current Deferred Revenue came in at $757000.0 for Q1 2026 at ARS Pharmaceuticals, up from $609000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $3.1 million in Q4 2022 to a low of $10000.0 in Q1 2023.
• The 5-year median for Current Deferred Revenue is $609000.0 (2025), against an average of $1.1 million.
• Across the five-year window, Current Deferred Revenue jumped 115.31% in 2022 and tumbled 82.03% in 2024, its largest moves.
• ARS Pharmaceuticals' Current Deferred Revenue stood at $3.1 million in 2022, then fell by 1.18% to $3.1 million in 2023, then sank by 82.03% to $557000.0 in 2024, then rose by 9.34% to $609000.0 in 2025, then advanced by 24.3% to $757000.0 in 2026.
• The last three Current Deferred Revenue figures came in at $757000.0 (Q1 2026), $609000.0 (Q4 2025), and $526000.0 (Q3 2025), per Business Quant data.